EUSA Pharma’s dinutuximab beta has gained European approval for its immunotherapy for children affected by a rare and devastating form of cancer, a move which exploits a gap in the market left ...

NICE has recommended EUSA Pharma’s neuroblastoma treatment Qarziba (dinutuximab beta) in final draft guidance after taking a lenient stance because of the rare nature of the disease, and after ...